Company Website:
http://www.bioasis.us
GUILFORD, Conn. -- (Business Wire)
Bioasis
Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or
“Bioasis”), a pre-clinical, research-stage biopharmaceutical company
developing its proprietary xB3™ platform technology
for the delivery of therapeutics across the blood-brain barrier (BBB)
and the treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases, today announced
that members of management will present at the following investor and
industry conferences in January 2019:
2nd
Annual Neuroscience Innovation Forum
-
Mark Day, Ph.D., director, president and chief executive officer will
deliver the Bioasis company presentation at the 2nd Annual
Neuroscience Innovation Forum on Mon., Jan. 6, 2019 at 12:05 p.m. PT
in the Heritage Room at the Marines' Memorial Club & Hotel, San
Francisco.
-
Dr. Mark Day will also co-chair the Advances in Rare & Orphan
Diseases panel on Mon., Jan. 6at 2:10 p.m. PT.
Biotech
Showcase™
-
Dr. Mark Day will deliver the Bioasis company presentation at Biotech
Showcase on Tues., Jan 7, 2019 at 10 a.m. PT in the Yosemite C
Ballroom at the Hilton San Francisco Union Square, San Francisco.
PepTalk
- The Protein Science Week
-
Mei Mei Tian, Ph.D., vice president, head of external research will
present, "The xB3 Platform Delivers a Protein-Based
Interleukin 1 Receptor Antagonist across the BBB and Ameliorates
Neuropathic Pain in a Preclinical Model" at PepTalk – The Protein
Science Week on Mon., Jan. 14, 2019 at 11:45 a.m. PT at the Hilton San
Diego Bayfront, San Diego.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., Director, President & Chief Executive Officer
ABOUT BIOASIS
Bioasis
Technologies Inc. is a biopharmaceutical company developing the xB3™
platform, a proprietary technology for the delivery of therapeutics
across the blood-brain barrier (BBB) and the treatment of CNS disorders
in areas of high unmet medical need, including brain cancers and
neurodegenerative diseases. The delivery of therapeutics across the BBB
represents the final frontier in treating neurological disorders. The
in-house development programs at Bioasis are designed to develop
symptomatic and disease-modifying treatments for brain-related diseases
and disorders. The company maintains headquarters in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the
symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more
information about the company, please visit www.bioasis.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005774/en/
Contacts:
Bioasis Technologies, Inc.
Catherine London
+1-917-763-2709
Catherine@bioasis.us
Source: Bioasis Technologies Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.